Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

被引：30

作者：

Nazha, Aziz ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Jain, Preetesh ^{[1
]}

Romo, Carlos ^{[1
]}

Jabbour, Elias ^{[1
]}

Quintas-Cardama, Alfonso ^{[1
]}

Luthra, Raja ^{[1
]}

Abruzzo, Lynne ^{[1
]}

Borthakur, Gautam ^{[1
]}

Ravandi, Farhad ^{[1
]}

Pierce, Sherry ^{[1
]}

O'Brien, Susan ^{[1
]}

Cortes, Jorge ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

HAEMATOLOGICA | 2013年 / 98卷 / 11期

关键词：

TYROSINE KINASE INHIBITORS; EARLY MOLECULAR RESPONSE; BCR-ABL1 TRANSCRIPT LEVELS; CHRONIC PHASE CML; BCR-ABL; IMATINIB; ACHIEVEMENT; INTERFERON; DASATINIB;

D O I：

10.3324/haematol.2013.090282

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. We analyzed 456 newly diagnosed chronic myeloid leukemia patients treated with tyrosine kinase inhibitors to determine their outcome based on their response at six months. Forty-four (10%) patients did not achieve major cytogenetic response at three months: 18 of 67 (27%) patients treated with imatinib 400; 18 of 196 (9%) with imatinib 800; and 8 of 193 (4%) with 2nd generation tyrosine kinase inhibitors. Among them, 19 (43%) achieved major cytogenetic response at six months and subsequently had an overall outcome similar to the patients who achieved a major cytogenetic response at three months. In conclusion, the response to tyrosine kinase inhibitors at three months is a static, one-time measure. Assessing the response at six months of patients with poor response at three months may provide a better predictor for long-term outcome.

引用

页码：1686 / 1688

页数：3

共 15 条

[1] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[2]

Cortes J, 2012, J NATL COMPR CANC NE, V10, pS1

[3] How I treat newly diagnosed chronic phase CML [J].

Cortes, Jorge ;

Kantarjian, Hagop .

BLOOD, 2012, 120 (07) :1390-1397

[4] Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results [J].

Hughes, Timothy ;

Deininger, Michael ;

Hochhaus, Andreas ;

Branford, Susan ;

Radich, Jerald ;

Kaecla, Jaspal ;

Baccarani, Michele ;

Cortes, Jorge ;

Cross, Nicholas C. P. ;

Druker, Brian J. ;

Gabert, Jean ;

Grimwade, David ;

Hehlmann, Ruediger ;

Kamel-Reid, Suzanne ;

Lipton, Jeffrey H. ;

Longtine, Janina ;

Martinelli, Giovanni ;

Saglio, Giuseppe ;

Soverini, Simona ;

Stock, Wendy ;

Goldman, John M. .

BLOOD, 2006, 108 (01) :28-37

[5] Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) [J].

Hughes, Timothy P. ;

Hochhaus, Andreas ;

Branford, Susan ;

Mueller, Martin C. ;

Kaeda, Jaspal S. ;

Foroni, Letizia ;

Druker, Brian J. ;

Guilhot, Francois ;

Larson, Richard A. ;

O'Brien, Stephen G. ;

Rudoltz, Marc S. ;

Mone, Manisha ;

Wehrle, Elisabeth ;

Modur, Vijay ;

Goldman, John M. ;

Radich, Jerald P. .

BLOOD, 2010, 116 (19) :3758-3765

[6] The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors [J].

Jabbour, Elias ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Shan, Jenny ;

Quintas-Cardama, Alfonso ;

Faderl, Stefan ;

Garcia-Manero, Guillermo ;

Ravandi, Farhad ;

Rios, Mary Beth ;

Cortes, Jorge .

BLOOD, 2011, 118 (17) :4541-4546

[7] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) [J].

Kantarjian, Hagop M. ;

Shah, Neil P. ;

Cortes, Jorge E. ;

Baccarani, Michele ;

Agarwal, Mohan B. ;

Soledad Undurraga, Maria ;

Wang, Jianxiang ;

Kassack Ipina, Juan Julio ;

Kim, Dong-Wook ;

Ogura, Michinori ;

Pavlovsky, Carolina ;

Junghanss, Christian ;

Milone, Jorge H. ;

Nicolini, Franck E. ;

Robak, Tadeusz ;

Van Droogenbroeck, Jan ;

Vellenga, Edo ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Hochhaus, Andreas .

BLOOD, 2012, 119 (05) :1123-1129

[8] Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy [J].

Kantarjian, Hagop M. ;

Baccarani, Michele ;

Jabbour, Elias ;

Saglio, Giuseppe ;

Cortes, Jorge E. .

CLINICAL CANCER RESEARCH, 2011, 17 (07) :1674-1683

[9] Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib [J].

Marin, David ;

Hedgley, Corinne ;

Clark, Richard E. ;

Apperley, Jane ;

Foroni, Letizia ;

Milojkovic, Dragana ;

Pocock, Christopher ;

Goldman, John M. ;

O'Brien, Stephen .

BLOOD, 2012, 120 (02) :291-294

[10] Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors [J].

Marin, David ;

Ibrahim, Amr R. ;

Lucas, Claire ;

Gerrard, Gareth ;

Wang, Lihui ;

Szydlo, Richard M. ;

Clark, Richard E. ;

Apperley, Jane F. ;

Milojkovic, Dragana ;

Bua, Marco ;

Pavlu, Jiri ;

Paliompeis, Christos ;

Reid, Alistair ;

Rezvani, Katayoun ;

Goldman, John M. ;

Foroni, Letizia .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) :232-238

← 1 2 →